STAT3 and diabetes mellitus: A recent study performed by Xu et al (Xu et al., 2018 ▶) concluded that miRNA-125a-5p, a regulator of glycolipid metabolism, should be considered a therapeutic target for diabetes due to the inhibition of hepatic lipogenesis and gluconeogenesis and elevation of glycogen synthesis through targeting STAT3 in diabetic rats and mice.